Epithelial barrier function assay
Determine the effect of your compound on epithelial barrier function, integrity, and tight cell junction dynamics in patient-derived organoids
discover moreNew paper
Evaluate epithelial barrier function with HUB Organoids
Compromised intestinal barrier function has been associated with a number of intestinal and systemic diseases, including inflammatory bowel disease (IBD), obesity, metabolic disorders, and graft versus host disease. Limited approved agents that target the intestinal epithelial barrier integrity are presently available for IBD due also to the lack of predictive and physiologically relevant preclinical models. Our new published paper discusses the development of a new HUB organoids-based model to assess drug efficacy and safety, as well as absorption, metabolism, transport and permeability.
Read this paper to:
Determine the effect of your compound on epithelial barrier function, integrity, and tight cell junction dynamics in patient-derived organoids
discover moreExplore our wide range of patient-derived organoid models from colon and small intestine biopsies of IBD patients
discover our biobankEnroll in our cost-effective drug screening platform and receive a quick read out of your drug’s efficacy and safety in patient-derived organoids
enroll now